CANNAINVESTOR Magazine February / March 2017 - Page 20

PRE-CLINICAL RESEARCH: BREAST CANCER STUDIES

Highlights

• Positive results in initial proof of concept study into the anti-cancer effects of THC-rich medical cannabis formulations

• Research conducted by world leading cannabis cancer scientists at Complutense University of Madrid, the results show that Zelda’s formulation of THC-rich oil is:

-Significantly more potent at reducing tumor growth than pure THC

-Equally as potent as Lapatanib in reducing tumor growth

• Initial positive results provide support for Zelda to continue its program of study evaluating its THC-rich medical cannabis formulations as anti-cancer therapeutics

Zelda Therapeutics will undertake pre-clinical research into breast cancer, brain cancer and pancreatic cancer. The company will also begin clinical trials in insomnia and dermatology conditions.

Zelda Therapeutics’ initial proof of concept study into the anti-cancer effects of its THC-rich medical cannabis formulation has produced positive results. The study was conducted on behalf of Zelda by world leading cannabis cancer researchers at Complutense University of Madrid, led by Professor Cristina Sánchez and Professor Manuel Guzmán.

Specifically, this initial study compared the anti-tumor responses of pure tetrahydrocannabinol (THC) versus the Zelda Therapeutics formulation of THC-rich oil and at the same time compare the potency against a standard chemotherapy drug, Lapatanib which is a tyrosine-kinase inhibitor of HER2 and EGFR, both receptors known to play an important role in breast cancer.

“The study showed that the Zelda Therapeutics’ formulation of THC-rich oil was significantly more potent at reducing tumor growth than pure THC and more importantly, was as potent as Lapatanib in reducing tumor growth.”

.

20